Positive outcome in clinical study to prevent radiation-induced dermatitis in breast cancer patients

APEIRON Biologics AG today announced that the clinical trial with their liposomal formulation of recombinant superoxide dismutase (project APN201) which started in March 2012 concluded with positive outcomes in all endpoints analyzed.

Press release